BioXcel Therapeutics Inc (FRA:BX2)
€ 1.892 0.006 (0.32%) Market Cap: 72.49 Mil Enterprise Value: 98.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 21/100

BioXcel Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 09, 2021 / 03:40PM GMT
Release Date Price: €30.12 (+0.77%)
Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay. Good afternoon, everyone, and welcome to the 4:40 p.m. session here on day 2 at the Goldman Sachs Global Healthcare Conference. My name is Graig Suvannavejh. I cover U.S. and European biopharma names here at the firm. It's my great pleasure to be hosting BioXcel Therapeutics in a fireside chat. And with that, joining from the company are CEO, Vimal Mehta; and Chief Commercialization Officer; William Kane. Gentlemen, it's good to see you both, and welcome.

Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, & Director

Thank you, Graig.

William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer

Thank you, Graig.

Graig Suvannavejh
Goldman Sachs Group, Inc., Research Division - Executive Director & Senior Equity Research Analyst

Okay, very well. Well, my sense is there's probably a number of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot